gynaecological cancer
Conditions
Interventions
control group (standard antiemetic therapy:0.75 mg palonosetron administered intravenously on day 1 and 6 mg dexamethasone administered intravenously on day 1 and 4 mg dexamethasone administered orall
Sponsors
Juntendo Nerima Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 20 years of age with gynaecological cancer who were scheduled to receive single-day chemotherapy with a carboplatin target area under the concentration curve of 5, and paclitaxel at 175 mg/m2. All patients had an Eastern Cooperative Oncology Group performance status of 0-2, adequate renal function, adequate hepatic function, and adequate marrow function. All patients provided written informed consent for their participation in the study.
Exclusion criteria
Exclusion criteria: receipt of any agent that could affect the study results (such as an antiemetic, steroid, or pimozide) before the start of chemotherapy; symptomatic brain metastasis; gastro-intestinal obstruction or any other condition that could provoke nausea and vomiting; and a known allergy or severe reaction to any of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response (CR, defined as complete absence of emetic events) in the delayed phase | — |
Countries
Japan
Contacts
Public ContactYayoi Sugimori
Juntendo Nerima Hospital Department of Obstetrics and Gynecology
Outcome results
None listed